EntityRisk’s Post

If you’re a vendor who works in the Life Sciences – hit my DMs. One of the things that has always driven me at Excedr is “How can we give back?” We do this for clients via our leases, but now The Biotech Startups Podcast has given us a much bigger platform to work with. So we just launched a Partners & Rewards network to the TBSP listener community as well. The Bioinformatics CRO, Tinybio, Kaleidoscope.bio, PhenoVista, Bunsen, BioProcure, Inc., Prendio, and Pliancy are already part of the preferred network, providing exclusive promos to our listeners…. Want to join them? We want to build the very best vendor partner network for biotech startups, so if you’d like to be a part of it, let’s get in touch. We’re carefully vetting the next group of vendor partners as we speak. P.S. - If you’re a biotech company and you want access to the exclusive discounts and offers from our network: 1. Tune in to the most recent episode of The Biotech Startups Podcast to get the listeners promo code. 2. Use the promo code on our Rewards page (link in comments) to get access to all the offers. P.P.S. - Is there a vendor you’d like to see on this list? Tag them below 👇 Justin Duplantis Grant Belgard 🧬💻 Sasha Dagayev 🇺🇦 Mandana Manzari H. James Evans Matthew Stoltz Ben Kellogg Dan Lord Matthew Smith Tyler Mizenko Jeannette Franklin Chris Ansaldi #biotechnology #lifesciences #biopharma

It was great to chat with Loretta TIOIELA 🇺🇦 last week on my transition from big pharma into VC! Thanks for taking the time with me Next Sequence® . transitioning #from #academia to big pharma, . experience as an #operator before vc, . how #drug and #therapeutics #commercialization strategies are important, . how #europe #biotech differs from the US, . the #opportunities offered by europe biotech, . the europe biotech #challenges and so much more

Our #TechBio #Investor #Series #Podcast #4 is out! Join us during this amazing podcast to discuss about : . transitioning #from #academia to big pharma, . experience as an #operator before vc, . how #drug and #therapeutics #commercialization strategies are important, . how #europe #biotech differs from the US, . the #opportunities offered by europe biotech, . the europe biotech #challenges and so much more with Sonal Pai , VC at First Spark Ventures : https://shorturl.at/tFHU0 First Spark Ventures is a deep tech venture capital firm, founded originally by #Eric #Schmidt and #Manish #Kothari, that invests in scientists globally. They specialize in advanced computing, digital biology and biotech, and cyber-physical systems.

My colleague Joe Daccache, Ph.D. and I had the pleasure to chat with Carina Clingman, PhD and Alison Hall from Building Biotechs: A Podcast by Recruitomics Consulting about #companycreation, starting a #biotech, and how you can try to make it all work. I know we've leveraged much of this building Suono Bio with Giovanni Traverso and #RobertLanger. https://lnkd.in/gUvgKKVC What did we touch on: 🚀 Being a founder is "the worst job you could ever choose ever": Its hard, unlimited hours, and highly nebulous. its also the best job ever because you are discovering #science no one else has that can have #patientimpact 🗺 You need a clear #pipeline strategy: There are "theoretical" market problems (that seemingly have a large market value but where those dollars don't actually change hands) and then actual problems, the latter which #payers will actually pay for. You need to address a problem that you can get #reimbursed for. 💭 Communication is key: You need to be able to communicate the why and how of your #startup succinctly. I can't tell you how many times we hear #founder pitches at our BroadOak Capital Partners #BioTools fund where you're left wondering what the company is actually trying to do. Explain why clearly, tie it to the market and #patients, and paint the picture of how the company will get there. Don't leave #VC's wondering what you do. #precisionmedicine #cgt #newco #biotech #pharma #venture #investing

Add market research to your scientific R&D, Test the rigour of the market fit - and THEN build/commercialise around it. Sadly, that's not always the case when building a start-up biotech company. Sometimes market research is an afterthought because people, usually scientists are so enamoured with how much faster they will get an assay done, that they don't realise that no one cares about how much faster they can do it. Product/Market misalignment is one of the many banes start-ups have because if it isn't done with conscientious thought to solve a problem, you're going to have a hard time hiring talent and marketing the product. This is a straight forward conundrum when it's laid out but you'll be surprised how many companies constantly do this. Martina Neville, PhD and I had a brilliant talk with Amber Penrose, founder of Moxee on the latest Market Your Science podcast about her experiences in using marketing and the lessons she's learned as well as the observations that come off her learnings to the start-ups she works with. Links in the comments. Do you think product misalignment is commonplace in the biopharma space?

Time truly does fly. 🕰️ It's hard to believe that it's been over six months since I sat down for an enlightening conversation with Philipp Baaske, CEO of NanoTemper Technologies Soon, we'll be reconnecting in person at Bio Europe, organized by EBD Group in Munich. 🔬 For those attending Bio Europe, or even if you're a biotech enthusiast, are you gearing up to converse with Philipp? To fuel your discussions, here are the most impactful takeaways from our podcast episode: 𝐓𝐡𝐞 𝐏𝐨𝐰𝐞𝐫 𝐨𝐟 𝐅𝐨𝐜𝐮𝐬 𝐚𝐧𝐝 𝐃𝐞𝐜𝐢𝐬𝐢𝐯𝐞𝐧𝐞𝐬𝐬: (36:08) "You have to take the hard decisions...It's full focus on the one thing, really push it." (09:51) "Absolute Focus on the Things You Can Influence." 𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐚𝐧𝐝 𝐄𝐧𝐠𝐚𝐠𝐢𝐧𝐠 𝐰𝐢𝐭𝐡 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫𝐬: (40:18) "First of all, I disagree with Steve Jobs, it's important to talk with customers about their problems, but it's really about the problem, not talking about a technical solution." (01:14:20) "Startup advice: focus on sales and steady growth." 𝐄𝐦𝐛𝐫𝐚𝐜𝐢𝐧𝐠 𝐚𝐧𝐝 𝐋𝐞𝐚𝐫𝐧𝐢𝐧𝐠 𝐟𝐫𝐨𝐦 𝐅𝐚𝐢𝐥𝐮𝐫𝐞𝐬: (52:17) "If you don't fail, you do something wrong because if it always works you don't lose the risky thing you do, you just do the easiest thing." (45:26) "Overcoming Failure in Startups and Drug Discovery." 𝐓𝐫𝐮𝐬𝐭 𝐚𝐧𝐝 𝐓𝐞𝐚𝐦 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬: (19:08) "I think this is an important part not micromanaging your team to create a larger entity." (1:49:52) "One toxic person can kill your whole team." (1:57:15) "Trust the founders as they do the best with your money." 𝐓𝐡𝐞 𝐈𝐧𝐭𝐞𝐫𝐬𝐞𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐚𝐧𝐝 𝐁𝐢𝐨𝐥𝐨𝐠𝐲: (47:20) "You get a molecular touch to it... this is a completely new pathway, this is very exciting." (01:03:21) "Experimenting in microgravity: sending projects to the ISS." 𝐋𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩 𝐚𝐧𝐝 𝐎𝐫𝐠𝐚𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐮𝐥𝐭𝐮𝐫𝐞: (1:31:21) "A leader alone is nothing, it's just a person; it's always the followers who are important." (1:33:15) "Tell this person it's wrong, don't tell them they're stupid; it's honesty and transparency." 𝐁𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐁𝐚𝐫𝐫𝐢𝐞𝐫𝐬 𝐚𝐧𝐝 𝐏𝐮𝐬𝐡𝐢𝐧𝐠 𝐁𝐨𝐮𝐧𝐝𝐚𝐫𝐢𝐞𝐬: (02:03:19) "When something was impossible in the past reconsider it because the situation in the past was different and now and in the future, new technology means things which have been impossible in the past may now be possible." (01:58:25) "Advice to Younger Self: Do Your Thing and Reconsider the Impossible." (1:55:08) "You have to break the rules as a startup; you do new things." Feel the inspiration from these takeaways. (Link to the full episode in the comments) 🎧 Which quote struck a chord with you? Engage, share, and let's keep the dialogue alive!

"Remember, AI's value lies in delivering better drugs, not just algorithms." -Its amazing to see Dave Latshaw II, PhD, MBA, getting an opportunity to share one of the key reasons we started BioPhy. 👨🔬 Great panel lead by Zach Taft, MBA, Co-Founder, Clinical Research Innovation Consortium (CRIC), Memorial Sloan Kettering Cancer Center 🔬 Accelerating Drug Development: Harnessing AI as a Problem-Solving Tool "Explore the latest in AI/ML investments transforming drug discovery. Case studies showcase AI's role in drug development. From research to clinical, AI enhances efficiency. Cutting-edge advances like LLMs revolutionize drug discovery. Remember, AI's value lies in delivering better drugs, not just algorithms. Prioritize rigorous clinical validation for investor and patient confidence. Join us to invest in a future where AI serves patients and drives real impact."

📣 The latest season of Cut The Chat – Life Science Insider Podcast starts with a deep dive into biotech investment strategies with Stephanie Oestreich. Discover the crucial role of strategic funding in accelerating medical breakthroughs. Listen to the episode now and join the conversation on advancing cures. #BiotechLeadership #InnovationMatters #CutTheChat #LifeScienceInsider #CutTheChatPodcast

🌟 Exciting Episode Alert! 🌟 Join us on Investor Connect as Hall dives into the world of early-stage investments with Brian Cain, President of Keiretsu Forum Philadelphia Chapter. 🚀 Listen to the full episode here: https://ow.ly/RXiw50R9sfs Brian Cain, with his extensive experience in Market Research and Business Intelligence within major pharmaceuticals like J & J and Merck, brings a unique perspective to the table. 🌍 Discover how he transitioned from Big Pharma to empowering promising biotech startups! 🧠 Dive deep into emerging investment trends like AI and glean expert advice on navigating this dynamic landscape. Whether you're an investor or entrepreneur, this episode promises invaluable takeaways! 🚀

🌟 Exciting Episode Alert! 🌟 Join us on Investor Connect as Hall dives into the world of early-stage investments with Brian Cain, President of Keiretsu Forum Philadelphia Chapter. 🚀 Listen to the full episode here: https://ow.ly/RXiw50R9sfs Brian Cain, with his extensive experience in Market Research and Business Intelligence within major pharmaceuticals like J & J and Merck, brings a unique perspective to the table. 🌍 Discover how he transitioned from Big Pharma to empowering promising biotech startups! 🧠 Dive deep into emerging investment trends like AI and glean expert advice on navigating this dynamic landscape. Whether you're an investor or entrepreneur, this episode promises invaluable takeaways! 🚀